Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

The purpose of the study was to investigate the effect of food intake on the pharmacokinetics and metabolism as well as the relative bioavailability of bosentan. Sixteen healthy male subjects were treated in a randomized, four-way, crossover design with single oral doses of 125 mg bosentan, given as one tablet (with or without food), two tablets of 62.5 mg (with food), and a suspension (without food). The pharmacokinetic parameters of bosentan (and also three of its metabolites) were very similar after the four treatments: geometric means for Cmax and AUC0-infinity, ranged from 1.3 to 1.6 microg/ml and from 7.8 to 8.9 microg x h/ml, respectively, and median t(max) from 3.0 to 4.0 hours. The bioavailability of the 125 mg tablet relative to that of the suspension, both given fasted, was 102%. In the presence of food, Cmax and AUC0-max increased by 22% and 10%, respectively, whereas the two 62.5 mg tablets were bioequivalent to the 125mg tablet, both under fed conditions. The pharmacokinetics of the metabolites was independent of the treatment administered. In conclusion, bosentan bioavailability from the newly developed 125 mg tablet formulation is similar to that of the suspension, and food intake does not influence its pharmacokinetics to a clinically relevant extent.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. L. M. van Giersbergen and J. Dingemanse Comparative Investigation of the Pharmacokinetics of Bosentan in Caucasian and Japanese Healthy Subjects J. Clin. Pharmacol., January 1, 2005; 45(1): 42 - 47. [Abstract] [Full Text] [PDF]

				K. W Kenyon and J. M Nappi Bosentan for the Treatment of Pulmonary Arterial Hypertension Ann. Pharmacother., July 1, 2003; 37(7): 1055 - 1062. [Abstract] [Full Text] [PDF]

				P. L. M. van Giersbergen, G. Popescu, F. Bodin, and J. Dingemanse Influence of Mild Liver Impairment on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor Antagonist J. Clin. Pharmacol., January 1, 2003; 43(1): 15 - 22. [Abstract] [Full Text]